A similar effect was seen when treating primary samples from proteasome inhibitor-refractory MM patients with a combination of selinexor, a clinical XPO1 inhibitor, and bortezomib or carfilzomib (Turner et al., 2016b). This evidence concerns the gene XPO1 and Miyoshi myopathy.